Table 3.

Combination index (CI) and dose reduction index (DRI) values for the combination therapies as indicated, in SKRC7 and SKRC17 cell lines.

	SKRC7 CI (DRI drug A;DRI drug B)			SKRC17 CI (DRI drug A;DRI drug B)
	FA 0.5	FA 0.75	FA 0.9	FA 0.5	FA 0.75	FA 0.9
Compound A (drug A) + gefitinib (drug B)	1.07 (2.2;1.6)	1.06 (1.8;2.0)	1.1 (1.4;2.5)	0.85 (35.8;1.2)	0.8 (642.6;1.3)	0.78 (1528.2;1.3)
Cabozantinib (drug A) + gefitinib (drug B)	0.49 (2.2;41.9)	0.55 (1.8;177.0)	0.64 (1.6;748.7)	0.94 (11.01;1.2)	0.88 (120.0;1.2)	0.89 (1307.0;1.1)
Compound A (drug A) + 6AN (drug B)	0.93 (3.3;1.6)	0.81 (4.8;1.7)	0.72 (6.9;1.7)	0.21 (39.5;5.5)	0.24 (27.0;4.8)	0.29 (18. 5;4.2)
Cabozantinib (drug A) + 6AN (drug B)	2.21 (1.1;0.8)	1.84 (1.1;1.1)	1.55 (1.2;1.4)	0.29 (6.7;7.3)	0.37 (4.2;7.7)	0.49 (2.7;8.2)

The FA-values represent the fraction of cell viability affected by treatment. CI and DRI values are given for FA values of 0.5, 0.75, and 0.9.